期刊
NUCLEIC ACID THERAPEUTICS
卷 27, 期 5, 页码 251-259出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/nat.2017.0682
关键词
exon skipping; oligonucleotides; regulatory approval
资金
- COST Action [BM1207]
- SCOPE-DMD
- National Institute for Health Research [NF-SI-0515-10022] Funding Source: researchfish
Duchenne muscular dystrophy (DMD) is a rare, severe, progressive muscle-wasting disease leading to disability and premature death. Patients lack the muscle membrane-stabilizing protein dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is a therapeutic approach that aims to induce production of partially functional dystrophins. Recently, an AON targeting exon 51 became the first of its class to be approved by the United States regulators [Food and Drug Administration (FDA)] for the treatment of DMD. A unique aspect of the exon-skipping approach for DMD is that, depending on the size and location of the mutation, different exons need to be skipped. This challenge raises a number of questions regarding the development and regulatory approval of those individual compounds. In this study, we present a perspective on those questions, following a European stakeholder meeting involving academics, regulators, and representatives from industry and patient organizations, and in the light of the most recent scientific and regulatory experience.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据